;+scheduling.html/?q=disclaimer_index.html
| We're sorry, that page (http://www.bio-medicine.org/;+scheduling.html/?q=disclaimer_index.html) was not found. Search ;+scheduling html ?q=disclaimer_index html at Google Search ;+scheduling html ?q=disclaimer_index html at Yahoo Search ;+scheduling html ?q=disclaimer_index html at Msn |
Breaking Biology Technology:Sangart, Inc. Receives European Orphan Drug Designation for the Use of MP4CO in Patients With Sickle Cell Disease 2Sangart, Inc. Receives European Orphan Drug Designation for the Use of MP4CO in Patients With Sickle Cell Disease 3Critical Step Toward Commercialization of Pre-Symptomatic Diagnosis of Ovarian Cancer Achieved by Arrayit Diagnostics 2Critical Step Toward Commercialization of Pre-Symptomatic Diagnosis of Ovarian Cancer Achieved by Arrayit Diagnostics 3Critical Step Toward Commercialization of Pre-Symptomatic Diagnosis of Ovarian Cancer Achieved by Arrayit Diagnostics 4New antioxidant compounds have been identified in foods such as olive oil, honey and nuts 2
[0] Quest Diagnostics Declares Quarterly Cash Dividend[0] Sangart, Inc. Receives European Orphan Drug Designation for the Use of MP4CO in Patients With Sickle Cell Disease[0] Critical Step Toward Commercialization of Pre-Symptomatic Diagnosis of Ovarian Cancer Achieved by Arrayit Diagnostics[0] New antioxidant compounds have been identified in foods such as olive oil, honey and nuts
Breaking Medicine Technology:Ascension Orthopedics Hires Key Senior Executives 2BioCryst Pharmaceuticals Elects Charles A. Sanders to its Board of Directors 2BioCryst Pharmaceuticals Elects Charles A. Sanders to its Board of Directors 3BioCryst Pharmaceuticals Elects Charles A. Sanders to its Board of Directors 4Drug Candidates in Pipeline Offer Potential for Parkinson's Disease Therapeutics Market, Says Frost & Sullivan 2Drug Candidates in Pipeline Offer Potential for Parkinson's Disease Therapeutics Market, Says Frost & Sullivan 3ORTHOWORLD Releases Position Paper on Healthcare Reform 53758 1ORTHOWORLD Releases Position Paper on Healthcare Reform 53758 2MaxLife Fund Corp announces cancellation of 14 050 000 Common Shares 53754 1MaxLife Fund Corp announces cancellation of 14 050 000 Common Shares 53754 2Sagent Pharmaceuticals Announces Launch of First Two Oncolytic Products 3A Fludarabine Phosphate for Injection USP and Epirubicin Hydrochloride Injec 53750 1Sagent Pharmaceuticals Announces Launch of First Two Oncolytic Products 3A Fludarabine Phosphate for Injection USP and Epirubicin Hydrochloride Injec 53750 2
| Copyright © 2003-2007 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |